• 中国科技论文统计源期刊
  • 中国科技核心期刊
  • 中国高校优秀期刊
  • 安徽省优秀科技期刊

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

产碳青霉烯酶肺炎克雷伯菌感染82例药物治疗分析

张弢 ,  严育忠 ,  包红 ,  赵才兴 ,  陈美红

downloadPDF
文章导航 > 蚌埠医学院学报  > 2013,  37 > 7: (872-875)  
引用本文:
shu
Citation:
shu

产碳青霉烯酶肺炎克雷伯菌感染82例药物治疗分析

  • 1.

    1. 上海市浦东医院药剂科;

  • 2.

    2. 上海市浦东医院检验科;

  • 3.

    3. 上海市浦东医院呼吸科

    • 作者简介: 张弢(1963－)，男，主管药师．
  • 基金项目:

The drug analysis of 82 cases infected by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae strains

  • 1.

    1. Department of Pharmacy;

  • 2.

    2. Department of Clinical Laboratory;

  • 3.

    3. Department of Pneumology, Pudong Hospital, Shanghai 201300, China

  • 摘要: 目的：探讨我院产碳青霉烯酶(KPC)肺炎克雷伯菌感染患者的确切死亡率、常见危险因素与药物治疗之间的关系。方法：借助电子医疗记录，通过图表，回顾性分析82例产KPC细菌感染的患者(重复检出的患者只记录1次)的临床信息。结果：82例患者中，66例样本产KPC同时产超广谱内酰胺酶(ESBL)，16例样本单产KPC，病死率分别为30例(45.5%)和5例(31.3%)，差异无统计学意义(P0.05)。Cox回归分析：KPC菌株产ESBL使用硫酸多黏菌素B治疗有明显的影响(P0.01)。结论：使用硫酸多黏菌素B治疗产ESBL患者有一定的效果。
    Abstract: Objective: To explore the relationship between the exact mortality,common risk factors and medication data of the patients infected byKlebsiella pneumoniaecarbapenemase(KPC) production strains in this region.Methods:With the help of electric medical record and the chart,the clinical data of 82 cases infected by KPC-producing strains in department of microbiology in our hospital were analyzed retrospectively.Results:Among these 82 patients,66 cases were infected by KPC / ESBL co-producing isolates,16 cases were infected by KPC producing isolates only.The mortality was 30 cases(45.5%) and 5 cases(31.3%) respectively,and there was no statistical significance(P0.05).In Cox regression analysis,treatment with sulfuric acid polymyxin B had obvious effect(P0.01). Conclusions:The treatment with sulfuric acid polymyxin B had certain herapeutic effect on patients infected by KPC-producing strains.
  • [1] Bratu S,Landman D,Haag R,et al.Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City:a new threat to our antibiotic armamentarium[J].Arch Intern Med,2005,165(12):1430-1435.
    [2] Nordmann P,Cuzon G,Naas T.The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria[J].Lancet Infect Dis,2009,9(4):228-236.
    [3] Petrella S,Ziental-Gelus N,Mayer C,et al.Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A -lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France[J].Antimicrob Agents Chemother,2008,52(10):3725-3736.
    [4] Samuelsen O,Naseer U,Tofteland S,et al.Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden[J].J Antimicrob Chemother,2009,63(4):654-658.
    [5] Endimiani A,Hujer AM,Perez F,et al.Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA [J].J Antimicrob Chemother,2009,63(3):427-437.
    [6] Li C,Du X,Kuti JL,et al.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections[J].Antimicrob Agents Chemother,2007,51(5):1725-1730.
    [7] Li C,Kuti JL,Nightingale CH,et al.Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients[J].J Clin Pharmacol,2006,46(10):1171-1178.
    [8] Nation RL,Li J.Colistin in the 21st century[J].Curr Opin Infect Dis,2009,22(6):535-543.
    [9] 王艳艳,刘红,杜昕,等.泛耐药肺炎克雷伯菌株的医院内流行特性的研究[J].中华微生物与免疫学杂志,2011,31(3):208-212
    [10] Giske CG,Gezelius L,Samuelsen,et al.A sensitive and specific phenotypic assay for detection of metallo--lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenyl boronic acid,dipicolinic acid and cloxacillin[J].Clin Microbiol Infect,2011,17(4):552-556.
    [11] Queenan AM,Bush K.Carbapenemases:the versatile -lactamases[J].Clin Microbiol Rev,2007,20(3):440-458.
    [12] Patel G,Huprikar S,Factor SH,et al.Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies[J].Infect Control Hosp Epidemiol,2008,29(12):1099-1106.
    [13] Borer A,Saidel-Odes L,Riesenberg K,et al.Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia[J].Infect Control Hosp Epidemiol,2009,30(10):972-976.
    [14] Kelesidis T,Karageorgopoulos DE,Kelesidis I,et al.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae:a systematic review of the evidence from microbiological and clinical studies[J].J Antimicrob Chemother,2008,62(5):895-904.
    [15] Elemam A,Rahimian J,Mandell W.Infection with panresistant Klebsiella pneumoniae:a report of 2 cases and a brief review of the literature[J].Clin Infect Dis,2009,49(2):271-274.
    [16] Souli M,Galani I,Antoniadou A,et al.An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K.pneumoniae in a Greek University Hospital:molecular characterization,epidemiology,and outcomes[J].Clin Infect Dis,2010,50(3):364-373.
    [17] Falagas ME,Maraki S,Karageorgopoulos DE,et al.Antimicrobial susceptibility of multidrug-resistant(MDR) and extensively drug- resistant(XDR) Enterobacteriaceae isolates to fosfomycin[J].Int J Antimicrob Agents,2010,35(3):240-243.
    [18] Urban C,Mariano N,Rahal JJ.In Vitro Double and triple bactericidal activities of doripenem,polymyxin B and rifampin against multidrug-resistant acinetobacter baumannii,Pseudomonas aeruginosa,Klebsiella pneumoniae and Escherichia coli [J]. Antimicrob Agents Chemother,2010,54(6):2732-2734.
    [19] Schwaber MJ,Klarfeld-Lidji S,Navon-Venezia S,et al.Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality[J].Antimicrob Agents Chemother,2008,52(3):1028-1033.
    [20] Falagas ME,Rafailidis PI,Kofteridis D,et al.Risk factors of carbapenem-resistant Klebsiella pneumoniae infections:a matched case control study[J].J Antimicrob Chemother,2007,60 (5):1124-1130.
    [21] Mendes RE,Bell JM,Turnidge JD,et al.Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid(blaKPC-2 plus qnrB4) and a blaIMP-4 gene[J].Antimicrob Agents Chemother,2008,52(2):798-799.
    [22] Naas T,Cuzon G,Villegas MV,et al.Genetic structures at the origin of acquisition of the -lactamase bla KPC gene [J].Antimicrob Agents Chemother,2008,52(4):1257-1263.
    [23] Tenover FC,Arbeit RD,Gcering RV,et al.Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis criteria for bacterial strain typing[J].J Clin Microbiol,1995,33(9):2233-2239.
  • [1] 朱敬蕊 , 段缓 , 崔琢 , 张向君 . 成年住院病人感染耐碳青霉烯类肺炎克雷伯菌的危险因素研究. 蚌埠医学院学报, 2021, 46(9): 1201-1203, 1207. doi: 10.13898/j.cnki.issn.1000-2200.2021.09.012
    [2] 何源沁 , 徐元宏 , 王中新 , 沈继龙 , 费广鹤 . 下呼吸道产超广谱β-内酰胺酶肺炎克雷伯菌及大肠埃希菌的耐药性基因型分析. 蚌埠医学院学报, 2008, 33(6): 648-651.
    [3] 王璐 , 高绪锋 , 张凤丽 , 胡燕云 , 黄颖 , 徐元宏 . 耐碳青霉烯肺炎克雷伯菌耐药基因检测及其同源性分析. 蚌埠医学院学报, 2019, 44(1): 107-110. doi: 10.13898/j.cnki.issn.1000-2200.2019.01.030
    [4] 张倩茹 , 李甲 , 郑岚 . 耐碳青霉烯肺炎克雷伯菌耐药率及同源性分析. 蚌埠医学院学报, 2020, 45(8): 1091-1093. doi: 10.13898/j.cnki.issn.1000-2200.2020.08.026
    [5] 李静 , 耿志军 , 郑晶 , 王涛 , 应冲涛 , 郭普 . 胶体金免疫层析法快速检测CRE碳青霉烯酶的效果评价. 蚌埠医学院学报, 2021, 46(8): 1089-1092. doi: 10.13898/j.cnki.issn.1000-2200.2021.08.026
    [6] 王璐 , 黄新明 , 章杰 , 彭成 . 碳青霉烯酶抑制剂增强试验检测肠杆菌目细菌碳青霉烯酶表型的临床应用. 蚌埠医学院学报, 2022, 47(12): 1707-1711. doi: 10.13898/j.cnki.issn.1000-2200.2022.12.020
    [7] 陈菲 , 王璐 , 王静 . 肺炎克雷伯菌耐药与抗菌药物使用强度现况及其关联分析. 蚌埠医学院学报, 2019, 44(8): 1091-1096. doi: 10.13898/j.cnki.issn.1000-2200.2019.08.032
    [8] 李银华 . 某医院儿科头孢类抗生素使用情况及产ESBLs肺炎克雷伯菌和大肠埃希菌检出率. 蚌埠医学院学报, 2016, 41(3): 351-352. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.023
    [9] 靳双荣 , 张全福 . 172株肺炎克雷伯菌的临床分布及耐药性分析. 蚌埠医学院学报, 2011, 36(11): 1255-1256.
    [10] 孙红 , 郭普 , 钟政荣 , 王锦 , 李竟 . 对亚胺培南耐药的肺炎克雷伯菌KPC基因型分析. 蚌埠医学院学报, 2012, 36(10): 1232-1234.
    [11] 刘晓平 , 蔡朝阳 , 邵小华 , 陈梅远 . 肺炎克雷伯菌耐药性趋势及特征性分析. 蚌埠医学院学报, 2013, 37(3): 339-342.
    [12] 程招敏 , 陈泳余 , 彭方 , 蓝锴 , 周强 , 柯培锋 . 多种中药对泛耐药肺炎克雷伯菌体外抗菌活性筛选. 蚌埠医学院学报, 2020, 45(4): 515-518, 522. doi: 10.13898/j.cnki.issn.1000-2200.2020.04.025
    [13] 高春明 , 李家斌 , 程君 , 赵守松 . 产超广谱β-内酰胺酶大肠埃希菌耐药性分析. 蚌埠医学院学报, 2008, 33(5): 531-532.
    [14] 吴祥林 , 沈继龙 , 徐元宏 . 产超广谱β-内酰胺酶大肠埃希菌耐药表型和基因型分析. 蚌埠医学院学报, 2008, 33(5): 605-608.
    [15] 方四倍 . 55株大肠埃希菌产超广谱-内酰胺酶检测及耐药性分析. 蚌埠医学院学报, 2013, 37(9): 1185-1186.
    [16] 周杰 , 徐康立 , 张鲍虎 , 张莉 , 杨书才 , 张扬 . 产超广谱β-内酰胺酶大肠埃希菌耐药性及基因型分析. 蚌埠医学院学报, 2018, 43(8): 1060-1063. doi: 10.13898/j.cnki.issn.1000-2200.2018.08.026
    [17] 张伦军 , 丁晓琳 , 郭普 , 钟政荣 , 沈继龙 . 耐亚胺培南铜绿假单胞菌的耐药性及超广谱-内酰胺酶的基因分析. 蚌埠医学院学报, 2013, 37(10): 1328-1330.
    [18] 黄峰 , 许元元 , 秦淑国 . 耐碳青霉烯类肺炎克雷伯菌耐药机制研究. 蚌埠医学院学报, 2017, 42(3): 379-382. doi: 10.13898/j.cnki.issn.1000-2200.2017.03.030
    [19] 孙立宁 , 孙明强 , 刘爱玲 , 李艳 . 小儿呼吸道感染产超广谱β-内酰胺酶菌株药敏分析. 蚌埠医学院学报, 2007, 32(4): 476-477.
    [20] 石莹 , 张玉心 , 夏俊 . 产超广谱-内酰胺酶细菌耐药性的检测进展. 蚌埠医学院学报, 2012, 36(1): 122-125.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3402
  • HTML全文浏览量:  386
  • PDF下载量:  114
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-09-28
  • 刊出日期:  2013-07-15

产碳青霉烯酶肺炎克雷伯菌感染82例药物治疗分析

    作者简介: 张弢(1963－)，男，主管药师．
  • 1. 1. 上海市浦东医院药剂科;
  • 2.  2. 上海市浦东医院检验科;
  • 3.  3. 上海市浦东医院呼吸科
  • 收稿日期: 2012-09-28
  • 网络出版日期: 2013-07-15
基金项目: 

摘要: 目的：探讨我院产碳青霉烯酶(KPC)肺炎克雷伯菌感染患者的确切死亡率、常见危险因素与药物治疗之间的关系。方法：借助电子医疗记录，通过图表，回顾性分析82例产KPC细菌感染的患者(重复检出的患者只记录1次)的临床信息。结果：82例患者中，66例样本产KPC同时产超广谱内酰胺酶(ESBL)，16例样本单产KPC，病死率分别为30例(45.5%)和5例(31.3%)，差异无统计学意义(P0.05)。Cox回归分析：KPC菌株产ESBL使用硫酸多黏菌素B治疗有明显的影响(P0.01)。结论：使用硫酸多黏菌素B治疗产ESBL患者有一定的效果。

English Abstract

    全文HTML

参考文献 (23)

目录

    /

    返回文章
    返回

    版权所有© 2019《蚌埠医学院学报》编辑部 皖ICP备06000434号-1

    地址：安徽省蚌埠市东海大道2600号 邮编：233030

    电话：0552-3175456 Email：byxb@vip.163.com

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net   百度统计